Energex System's Experimental Non-Pharmicalogical Treatment Promising in Reduci

[Guest guest]

November 22, 2004 12:47 PM US Eastern Timezone

Energex System's Experimental Non-Pharmicalogical Treatment Promising in

Reducing Viral Load in Hepatitis C Patients

BIOWIRE2K

EMERSON, N.J.--(BUSINESS WIRE)--Nov. 22, 2004--Energex Systems, Inc. announced

today that preliminary results of its Hepatitis C clinical trial have shown

consistent and drastic reductions in viral load in trial participants treated

with its Hemo-Modulator technology. The trial is being conducted under an

Investigational Device Exemption (IDE) that was granted by the Federal Food and

Drug Administration (FDA) in October, 2004.

http://home.businesswire.com/portal/site/altavista/index.jsp?ndmViewId=news_view\

& newsId=20041122005667 & newsLang=en

[Guest guest]

November 22, 2004 12:47 PM US Eastern Timezone

Energex System's Experimental Non-Pharmicalogical Treatment Promising in

Reducing Viral Load in Hepatitis C Patients

BIOWIRE2K

EMERSON, N.J.--(BUSINESS WIRE)--Nov. 22, 2004--Energex Systems, Inc. announced

today that preliminary results of its Hepatitis C clinical trial have shown

consistent and drastic reductions in viral load in trial participants treated

with its Hemo-Modulator technology. The trial is being conducted under an

Investigational Device Exemption (IDE) that was granted by the Federal Food and

Drug Administration (FDA) in October, 2004.

http://home.businesswire.com/portal/site/altavista/index.jsp?ndmViewId=news_view\

& newsId=20041122005667 & newsLang=en

[Guest guest]

November 22, 2004 12:47 PM US Eastern Timezone

Energex System's Experimental Non-Pharmicalogical Treatment Promising in

Reducing Viral Load in Hepatitis C Patients

BIOWIRE2K

EMERSON, N.J.--(BUSINESS WIRE)--Nov. 22, 2004--Energex Systems, Inc. announced

today that preliminary results of its Hepatitis C clinical trial have shown

consistent and drastic reductions in viral load in trial participants treated

with its Hemo-Modulator technology. The trial is being conducted under an

Investigational Device Exemption (IDE) that was granted by the Federal Food and

Drug Administration (FDA) in October, 2004.

http://home.businesswire.com/portal/site/altavista/index.jsp?ndmViewId=news_view\

& newsId=20041122005667 & newsLang=en

[Guest guest]

November 22, 2004 12:47 PM US Eastern Timezone

Energex System's Experimental Non-Pharmicalogical Treatment Promising in

Reducing Viral Load in Hepatitis C Patients

BIOWIRE2K

EMERSON, N.J.--(BUSINESS WIRE)--Nov. 22, 2004--Energex Systems, Inc. announced

today that preliminary results of its Hepatitis C clinical trial have shown

consistent and drastic reductions in viral load in trial participants treated

with its Hemo-Modulator technology. The trial is being conducted under an

Investigational Device Exemption (IDE) that was granted by the Federal Food and

Drug Administration (FDA) in October, 2004.

http://home.businesswire.com/portal/site/altavista/index.jsp?ndmViewId=news_view\

& newsId=20041122005667 & newsLang=en